TY - JOUR
T1 - Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis
AU - Mnich, Stephen J.
AU - Blanner, Patrick M.
AU - Hu, Liangbiao G.
AU - Shaffer, Alexander F.
AU - Happa, Fernando A.
AU - O'Neil, Shawn
AU - Ukairo, Okechukwu
AU - Weiss, Dave
AU - Welsh, Eric
AU - Storer, Chad
AU - Mbalaviele, Gabriel
AU - Ichijo, Hidenori
AU - Monahan, Joseph B.
AU - Hardy, Medora M.
AU - Eda, Hiroyuki
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2010/10
Y1 - 2010/10
N2 - In this report, we show that apoptosis signal-regulating kinase 1-/- (ASK1 KO) mice were resistant to inflammatory arthritis induced in the K/BxN serum transfer model of rheumatoid arthritis (RA). The p38 inhibitor, SD-0006 was administered to wild type (WT) mice as a comparator. Both ASK1 KO and p38 inhibition resulted in marked attenuation of edema, cartilage damage, bone resorption, and general inflammatory responses. Transcriptional profiling of mRNA prepared from paw tissue demonstrated that the production of many proinflammatory genes including cytokines, chemokines, and extracellular matrix degradative enzymes were maintained at basal levels by either ASK1 KO or prophylactic p38 MAPK inhibition. In the mouse whole blood (MWB) assay, tumor necrosis factor-α (TNF-α)-induced KC and CCL2 levels and also LPS-induced interleukin-6 (IL-6), CCL2, and KC levels in MWB from ASK1 KO were significantly lower than those from WT. Furthermore, both p38 and JNK were activated by TNF-α in human synovial fibroblasts isolated from RA patients (RASF). SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-α. In contrast, dual inhibition with both p38/JNK inhibitors almost completely abolished TNF-α-induced IL-6 production from these cells. Ablation of ASK1 expression in RASF using siRNA for ASK1 resulted in inhibition of TNF-α-induced IL-6 and PGE2 production. This study is the first to suggest that ASK1 is critical for the development of RA and that ASK1 may be involved in the production of proinflammatory mediators in response to TNF-α stimulation in the RA joint.
AB - In this report, we show that apoptosis signal-regulating kinase 1-/- (ASK1 KO) mice were resistant to inflammatory arthritis induced in the K/BxN serum transfer model of rheumatoid arthritis (RA). The p38 inhibitor, SD-0006 was administered to wild type (WT) mice as a comparator. Both ASK1 KO and p38 inhibition resulted in marked attenuation of edema, cartilage damage, bone resorption, and general inflammatory responses. Transcriptional profiling of mRNA prepared from paw tissue demonstrated that the production of many proinflammatory genes including cytokines, chemokines, and extracellular matrix degradative enzymes were maintained at basal levels by either ASK1 KO or prophylactic p38 MAPK inhibition. In the mouse whole blood (MWB) assay, tumor necrosis factor-α (TNF-α)-induced KC and CCL2 levels and also LPS-induced interleukin-6 (IL-6), CCL2, and KC levels in MWB from ASK1 KO were significantly lower than those from WT. Furthermore, both p38 and JNK were activated by TNF-α in human synovial fibroblasts isolated from RA patients (RASF). SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-α. In contrast, dual inhibition with both p38/JNK inhibitors almost completely abolished TNF-α-induced IL-6 production from these cells. Ablation of ASK1 expression in RASF using siRNA for ASK1 resulted in inhibition of TNF-α-induced IL-6 and PGE2 production. This study is the first to suggest that ASK1 is critical for the development of RA and that ASK1 may be involved in the production of proinflammatory mediators in response to TNF-α stimulation in the RA joint.
KW - Apoptosis signal-regulating kinase 1 (ASK1)
KW - C-jun N-terminal kinase (JNK)
KW - K/BxN serum transfer model
KW - Mitogen-activated protein kinase (MAPK)
KW - P38 MAPK
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=77957223838&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2010.06.023
DO - 10.1016/j.intimp.2010.06.023
M3 - Article
C2 - 20609399
AN - SCOPUS:77957223838
SN - 1567-5769
VL - 10
SP - 1170
EP - 1176
JO - International Immunopharmacology
JF - International Immunopharmacology
IS - 10
ER -